{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T04:16:40Z","timestamp":1793506600263,"version":"4.5.0"},"reference-count":45,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82102820"],"award-info":[{"award-number":["82102820"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82102821"],"award-info":[{"award-number":["82102821"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82304347"],"award-info":[{"award-number":["82304347"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.ejca.2025.115717","type":"journal-article","created":{"date-parts":[[2025,8,18]],"date-time":"2025-08-18T07:44:01Z","timestamp":1755503041000},"page":"115717","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Neoadjuvant chemoradiation with camrelizumab and nimotuzumab for initially inoperable esophageal squamous cell carcinoma: A single-arm phase 2 trial"],"prefix":"10.1016","volume":"228","author":[{"given":"Yuan","family":"He","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiquan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianguo","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haibo","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hangcheng","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueru","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingjing","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyu","family":"Mei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jieyong","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3232-5104","authenticated-orcid":false,"given":"Dong","family":"Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ejca.2025.115717_bib1","first-page":"17","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"10.1016\/j.ejca.2025.115717_bib2","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s11604-017-0693-0","article-title":"Treatment results of neoadjuvant chemoradiotherapy followed by radical esophagectomy in patients with initially inoperable thoracic esophageal cancer","volume":"36","author":"Morimoto","year":"2017","journal-title":"Jpn J Radiol"},{"key":"10.1016\/j.ejca.2025.115717_bib3","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.ejca.2022.09.035","article-title":"Patterns of care for relapsed oesophageal cancer after initial curative trimodality therapy: Long-term follow-up of the SAKK 75\/08 trial","volume":"177","author":"Panje","year":"2022","journal-title":"Eur J Cancer"},{"issue":"2","key":"10.1016\/j.ejca.2025.115717_bib4","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.radonc.2017.06.019","article-title":"The impact of histology on recurrence patterns in esophageal cancer treated with definitive chemoradiotherapy","volume":"124","author":"Xi","year":"2017","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ejca.2025.115717_bib5","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1186\/s13014-022-02116-0","article-title":"A retrospective study comparing definitive chemoradiotherapy vs. Chemoradiotherapy followed by surgery in T4 esophageal squamous cell carcinoma patients who were downstaged after neochemoradiotherapy","volume":"17","author":"Zhang","year":"2022","journal-title":"Radiat Oncol"},{"issue":"13","key":"10.1016\/j.ejca.2025.115717_bib6","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1056\/NEJMoa2032125","article-title":"Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer","volume":"384","author":"Kelly","year":"2021","journal-title":"N Engl J Med"},{"issue":"10302","key":"10.1016\/j.ejca.2025.115717_bib7","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/S0140-6736(21)01234-4","article-title":"Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study","volume":"398","author":"Sun","year":"2021","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.ejca.2025.115717_bib8","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1001\/jama.2021.12836","article-title":"Effect of camrelizumab vs placebo added to chemotherapy on survival and Progression-Free survival in patients with advanced or metastatic esophageal squamous cell carcinoma: the ESCORT-1st randomized clinical trial","volume":"326","author":"Luo","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.ejca.2025.115717_bib9","doi-asserted-by":"crossref","unstructured":"Peng F., Bao Y., Cheng C., Induction chemotherapy plus camrelizumab followed by concurrent chemoradiotherapy in patients with unresectable locally advanced esophageal squamous cell carcinoma (ImpactCRT): a single-arm, phase II trial. ASCO-GI. 2023;41(16_suppl):e16067-e16067..","DOI":"10.1200\/JCO.2023.41.16_suppl.e16067"},{"issue":"1","key":"10.1016\/j.ejca.2025.115717_bib10","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2021.1971418","article-title":"Addition of camrelizumab to docetaxel, cisplatin, and radiation therapy in patients with locally advanced esophageal squamous cell carcinoma: a phase 1b study","volume":"10","author":"Zhang","year":"2021","journal-title":"OncoImmunology"},{"key":"10.1016\/j.ejca.2025.115717_bib11","doi-asserted-by":"crossref","first-page":"S1124","DOI":"10.1016\/j.annonc.2022.07.1880","article-title":"Efficacy and safety of consolidative camrelizumab following definitive concurrent chemoradiotherapy in patients with locally advanced esophageal squamous cell cancer","volume":"33","author":"Wang","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2025.115717_bib12","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.ejca.2020.11.039","article-title":"Preoperative pembrolizumab combined with chemoradiotherapy for oesophageal squamous cell carcinoma (PALACE-1)","volume":"144","author":"Li","year":"2021","journal-title":"Eur J Cancer"},{"issue":"2","key":"10.1016\/j.ejca.2025.115717_bib13","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1007\/s10388-025-01113-y","article-title":"Investigating the synergistic effects of immunochemotherapy in esophageal squamous cell carcinoma","volume":"22","author":"Okui","year":"2025","journal-title":"Esophagus"},{"issue":"9","key":"10.1016\/j.ejca.2025.115717_bib14","doi-asserted-by":"crossref","first-page":"2549","DOI":"10.1038\/s41591-024-03064-w","article-title":"Neoadjuvant chemotherapy with or without camrelizumab in resectable esophageal squamous cell carcinoma: the randomized phase 3 ESCORT-NEO\/NCCES01 trial","volume":"30","author":"Qin","year":"2024","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.ejca.2025.115717_bib15","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-008229","article-title":"Short-course neoadjuvant radiotherapy combined with chemotherapy and toripalimab for locally advanced esophageal squamous cell carcinoma (SCALE- 1): a single- arm phase ib clinical trial","volume":"12","author":"Jiang","year":"2024","journal-title":"J Immunother Cancer"},{"issue":"1-2","key":"10.1016\/j.ejca.2025.115717_bib16","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1053\/j.seminoncol.2018.04.008","article-title":"Nimotuzumab: beyond the EGFR signaling cascade inhibition","volume":"45","author":"Mazorra","year":"2018","journal-title":"Semin Oncol"},{"issue":"1","key":"10.1016\/j.ejca.2025.115717_bib17","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1186\/s12876-022-02602-5","article-title":"Safety and efficacy analysis of chemoradiotherapy\/radiotherapy combined with nimotuzumab for treating unresectable oesophageal squamous cell carcinoma in elderly patients: a retrospective analysis","volume":"22","author":"Zhang","year":"2022","journal-title":"BMC Gastroenterol"},{"issue":"8","key":"10.1016\/j.ejca.2025.115717_bib18","doi-asserted-by":"crossref","first-page":"653","DOI":"10.2174\/1568009623666230315145937","article-title":"Efficacy and safety of concurrent chemoradiotherapy combined with nimotuzumab in elderly patients with esophageal squamous cell carcinoma: a prospective Real-world pragmatic study","volume":"23","author":"Yu","year":"2023","journal-title":"Curr Cancer Drug Targets"},{"issue":"11","key":"10.1016\/j.ejca.2025.115717_bib19","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1038\/s41416-023-02388-7","article-title":"Nimotuzumab plus concurrent chemo-radiotherapy in unresectable locally advanced oesophageal squamous cell carcinoma (ESCC): interim analysis from a phase 3 clinical trial","volume":"129","author":"Meng","year":"2023","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ejca.2025.115717_bib20","doi-asserted-by":"crossref","unstructured":"Dai L., Hung J., Hu L., et al. Efficacy of nimotuzumab plus concurrent chemo radiotherapy for unresectable esophageal cancer: a real world study. 2023ASTRO.2773;","DOI":"10.1016\/j.ijrobp.2023.06.2432"},{"issue":"2","key":"10.1016\/j.ejca.2025.115717_bib21","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/j.athoracsur.2014.03.015","article-title":"Epidermal growth factor receptor is a prognosis predictor in patients with esophageal squamous cell carcinoma","volume":"98","author":"Zhang","year":"2014","journal-title":"Ann Thorac Surg"},{"issue":"22","key":"10.1016\/j.ejca.2025.115717_bib22","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1111\/1759-7714.14995","article-title":"Cetuximab enhances radiosensitivity of esophageal squamous cell carcinoma cells by G2\/M\u2009cycle arrest and DNA repair delay through inhibiting p-EGFR and p-ERK","volume":"14","author":"Zhao","year":"2023","journal-title":"Thorac Cancer"},{"issue":"3","key":"10.1016\/j.ejca.2025.115717_bib23","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/j.celrep.2018.06.066","article-title":"ALIX regulates Tumor-Mediated immunosuppression by controlling EGFR activity and PD-L1 presentation","volume":"24","author":"Monypenny","year":"2018","journal-title":"Cell Rep"},{"issue":"3","key":"10.1016\/j.ejca.2025.115717_bib24","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s10388-024-01054-y","article-title":"Japanese classification of esophageal cancer, 12th edition: part I","volume":"21","author":"Mine","year":"2024","journal-title":"Esophagus"},{"issue":"1","key":"10.1016\/j.ejca.2025.115717_bib25","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/s13014-020-01518-2","article-title":"A study of concurrent chemoradiotherapy with weekly docetaxel and cisplatin for advanced esophageal squamous cell carcinoma with T4 and\/or M1 lymph node metastasis or locoregional recurrence","volume":"15","author":"Liu","year":"2020","journal-title":"Radiat Oncol"},{"issue":"1","key":"10.1016\/j.ejca.2025.115717_bib26","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1093\/jrr\/rraa110","article-title":"Long-term results of definitive chemoradiotherapy for unresectable locally advanced esophageal squamous cell carcinoma","volume":"62","author":"Ochi","year":"2021","journal-title":"J Radiat Res"},{"issue":"6","key":"10.1016\/j.ejca.2025.115717_bib27","doi-asserted-by":"crossref","first-page":"e465","DOI":"10.1097\/SLA.0000000000004564","article-title":"Multicenter randomized phase 2 trial comparing chemoradiotherapy and docetaxel plus 5-Fluorouracil and cisplatin chemotherapy as initial induction therapy for subsequent conversion surgery in patients with clinical T4b esophageal cancer","volume":"274","author":"Sugimura","year":"2021","journal-title":"Ann Surg"},{"issue":"12","key":"10.1016\/j.ejca.2025.115717_bib28","doi-asserted-by":"crossref","first-page":"e472","DOI":"10.1016\/S1470-2045(23)00412-6","article-title":"Global cancer surgery: pragmatic solutions to improve cancer surgery outcomes worldwide","volume":"24","author":"Are","year":"2023","journal-title":"Lancet Oncol"},{"issue":"22","key":"10.1016\/j.ejca.2025.115717_bib29","doi-asserted-by":"crossref","first-page":"5061","DOI":"10.1158\/1078-0432.CCR-24-1236","article-title":"Chemoradiotherapy and subsequent immunochemotherapy as conversion therapy in unresectable locally advanced esophageal squamous cell carcinoma: a phase II NEXUS-1 trial","volume":"30","author":"Wang","year":"2024","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.ejca.2025.115717_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2020.100916","article-title":"Tumor-targeting anti-EGFR x anti-PD1 bispecific antibody inhibits EGFR-overexpressing tumor growth by combining EGFR blockade and immune activation with direct tumor cell killing","volume":"14","author":"Li","year":"2021","journal-title":"Transl Oncol"},{"key":"10.1016\/j.ejca.2025.115717_bib31","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.102118","article-title":"A phase II clinical trial of toripalimab combined with neoadjuvant chemoradiotherapy in locally advanced esophageal squamous cell carcinoma (NEOCRTEC1901)","volume":"62","author":"Chen","year":"2023","journal-title":"eClinicalMedicine"},{"issue":"27","key":"10.1016\/j.ejca.2025.115717_bib32","doi-asserted-by":"crossref","first-page":"2796","DOI":"10.1200\/JCO.2018.79.1483","article-title":"Neoadjuvant chemoradiotherapy followed by surgery versus surgery alone for locally advanced squamous cell carcinoma of the esophagus (NEOCRTEC5010): a phase III multicenter, randomized, Open-Label clinical trial","volume":"36","author":"Yang","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2025.115717_bib33","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1056\/NEJMoa1112088","article-title":"Preoperative chemoradiotherapy for esophageal or junctional cancer","volume":"366","author":"van Hagen","year":"2012","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.ejca.2025.115717_bib34","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/S1470-2045(23)00060-8","article-title":"Toripalimab combined with definitive chemoradiotherapy in locally advanced oesophageal squamous cell carcinoma (EC-CRT-001): a single-arm, phase 2 trial","volume":"24","author":"Zhu","year":"2023","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.ejca.2025.115717_bib35","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1158\/2159-8290.CD-20-1808","article-title":"Therapeutic targeting of the tumor microenvironment","volume":"11","author":"Bejarano","year":"2021","journal-title":"Cancer Discov"},{"issue":"6","key":"10.1016\/j.ejca.2025.115717_bib36","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1038\/s41571-023-00757-y","article-title":"Improving outcomes in patients with oesophageal cancer","volume":"20","author":"Shah","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"issue":"11","key":"10.1016\/j.ejca.2025.115717_bib37","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1016\/j.ccell.2023.09.011","article-title":"Progenitor-like exhausted SPRY1+CD8+ t cells potentiate responsiveness to neoadjuvant PD-1 blockade in esophageal squamous cell carcinoma","volume":"41","author":"Liu","year":"2023","journal-title":"Cancer Cell"},{"issue":"3","key":"10.1016\/j.ejca.2025.115717_bib38","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003984","article-title":"Effect of neoadjuvant chemotherapy on the immune microenvironment in gastric cancer as determined by multiplex immunofluorescence and t cell receptor repertoire analysis","volume":"10","author":"Xing","year":"2022","journal-title":"J Immunother Cancer"},{"issue":"7","key":"10.1016\/j.ejca.2025.115717_bib39","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-008889","article-title":"Hypoxia inhibits the iMo\/cDC2\/CD8+ TRMs immune axis in the tumor microenvironment of human esophageal cancer","volume":"12","author":"Wu","year":"2024","journal-title":"J Immunother Cancer"},{"issue":"1","key":"10.1016\/j.ejca.2025.115717_bib40","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1245\/s10434-023-14352-z","article-title":"Potential predictive immune and metabolic biomarkers of tumor microenvironment regarding pathological and clinical response in esophageal cancer after neoadjuvant chemoradiotherapy: a systematic review","volume":"31","author":"Wang","year":"2023","journal-title":"Ann Surg Oncol"},{"issue":"3","key":"10.1016\/j.ejca.2025.115717_bib41","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1016\/j.ymthe.2021.11.015","article-title":"Spatial distribution and functional analysis define the action pathway of Tim-3\/Tim-3 ligands in tumor development","volume":"30","author":"Wang","year":"2022","journal-title":"Mol Ther"},{"issue":"1","key":"10.1016\/j.ejca.2025.115717_bib42","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1186\/s12967-023-04154-y","article-title":"Functional status and spatial architecture of tumor-infiltrating CD8+\u2009T cells are associated with lymph node metastases in non-small cell lung cancer","volume":"21","author":"Yang","year":"2023","journal-title":"J Transl Med"},{"issue":"11","key":"10.1016\/j.ejca.2025.115717_bib43","doi-asserted-by":"crossref","first-page":"3787","DOI":"10.1007\/s00262-023-03531-2","article-title":"PD-L1-expressing cancer-associated fibroblasts induce tumor immunosuppression and contribute to poor clinical outcome in esophageal cancer","volume":"72","author":"Kawasaki","year":"2023","journal-title":"Cancer Immunol Immunother"},{"issue":"15","key":"10.1016\/j.ejca.2025.115717_bib44","doi-asserted-by":"crossref","first-page":"2908","DOI":"10.1158\/1078-0432.CCR-23-0215","article-title":"Subsets of IFN signaling predict response to immune checkpoint blockade in patients with melanoma","volume":"29","author":"Horowitch","year":"2023","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.ejca.2025.115717_bib45","doi-asserted-by":"crossref","first-page":"7116","DOI":"10.1038\/s41467-024-51105-2","article-title":"Toripalimab plus chemotherapy and radiotherapy for treatment-naive advanced esophageal squamous cell carcinoma: a single-arm phase 2 trial","volume":"15","author":"Wu","year":"2024","journal-title":"Nat Commun"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804925005003?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804925005003?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T09:46:11Z","timestamp":1779702371000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804925005003"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":45,"alternative-id":["S0959804925005003"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2025.115717","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Neoadjuvant chemoradiation with camrelizumab and nimotuzumab for initially inoperable esophageal squamous cell carcinoma: A single-arm phase 2 trial","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2025.115717","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"115717"}}